DARA BioSciences Launches Soltamox in US
BioSciences (NASDAQ: DARA) announced today it has launched Soltamox®
(tamoxifen citrate) oral solution in the United States. Soltamox is
a new treatment option for breast cancer patients who are prescribed
tamoxifen therapy. DARA has exclusive U.S. rights to Soltamox from
Rosemont Pharmaceuticals, Ltd, UK.
Soltamox, liquid version of tamoxifen citrate (Photo: Business Wire)
Since its approval in 1977, tamoxifen has been used to treat millions of
women and men diagnosed with hormone-receptor-positive breast cancer.
Treatment with tamoxifen lowers the risk of breast cancer recurrence,
breast cancer in the opposite breast, and death from breast cancer.